Enodia Therapeutics SAS /
Kezar Life Sciences, Inc.
Kezar sells Sec61 program assets to Enodia
Source for the buyer and target: Kezar Life Sciences, Inc.
For the buyer and target.
“This ASSET PURCHASE AGREEMENT (this “ Agreement ”) is entered into as of March 6, 2026 (the “ Effective Date ”) by and between Enodia Therapeutics SAS, a French simplified joint stock company (société par actions simplifiée), having offices at 26 Rue Bosquet, 75007 Paris, France (“ Enodia ”) and Kezar Life Sciences, Inc., a Delaware corporation, having offices at 4000 Shoreline Court, Suite 300, South San Francisco, California 94080, United States ( “ Seller ”).”
Published 12 Mar 2026
Open the sourceWhat happened
Kezar Life Sciences agreed on March 6, 2026 to sell its Sec61-based discovery and development program assets, including the KZR-261 product candidate, to Enodia Therapeutics. Enodia took those assets and assumed certain related liabilities, while Kezar kept its zetomizomib program, cash and other excluded assets. Kezar received $800,000 at closing, with another $200,000 due later. [01]
The source
Everything on this page comes from the source below, quoted word for word.
Kezar sells Sec61 program assets to Enodia
This document is the source for the companies, stage and people on this page.
Open the sourceTimeline
Every date the source states, in order, each with the words it comes from. Anything marked ahead is a target the source gives, not something that has happened.
Agreement signed
“Kezar sells Sec61 program assets to Enodia Kezar Life Sciences agreed on March 6, 2026 to sell its Sec61-based discovery and development program assets, including the KZR-261 product candidate, to Enodia Therapeutics”
Open the source
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Get ProAlready a member? Sign in
Pro is open to everyone.
By email · Weekly